Work

Phase 1 study of dalotuzumab monotherapy and ridaforolimus–dalotuzumab combination therapy in paediatric patients with advanced solid tumours

Year: 2016

Type: article

Study design: Clinical Trial

Source: European Journal of Cancer

DOI: 10.1016/j.ejca.2016.03.084

Authors: Didier Frappaz, Sara M. Federico, Andrew D.J. Pearson, Lia Gore, Margaret E. Macy, Steven G. DuBois, Isabelle Aerts, Robert Iannone, Ryan Geschwindt, Arne Van Schanke, Rui Wang, Birgit Geoerger

Institutions: Institut d’Hématologie et d’Oncologie Pédiatrique, St. Jude Children's Research Hospital, Institute of Cancer Research, Royal Marsden Hospital, Children's Hospital Colorado, University of Colorado Anschutz, University of Colorado Denver, Dana-Farber Cancer Institute, Institut Curie, Merck & Co., Inc., Rahway, NJ, USA (United States), Université Paris-Sud, Institut Gustave Roussy

Language: English

Topic: Growth Hormone and Insulin-like Growth Factors

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Merck Sharp and Dohme

OpenAlex ID: W2364373762

FWCI: 3.347

Cites: 40

Cited by: 23

Related to: 10